Trial · NCT03677141
Adverse event totals18
The totals the trial posted for each group.
1 to 18 of 18
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group A1: Phase Ib Mosunetuzumab + CHOP | 2 | 3 |
| Total, all-cause mortality | Group A2: Phase Ib Mosunetuzumab + CHOP | 1 | 4 |
| Total, all-cause mortality | Group B: Phase Ib Mosunetuzumab + CHP-Pola | 6 | 8 |
| Total, all-cause mortality | Group C: Phase II Mosunetuzumab + CHOP | 9 | 40 |
| Total, all-cause mortality | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 5 | 40 |
| Total, all-cause mortality | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 3 | 22 |
| Total, other adverse events | Group A1: Phase Ib Mosunetuzumab + CHOP | 3 | 3 |
| Total, other adverse events | Group A2: Phase Ib Mosunetuzumab + CHOP | 4 | 4 |
| Total, other adverse events | Group B: Phase Ib Mosunetuzumab + CHP-Pola | 8 | 8 |
| Total, other adverse events | Group C: Phase II Mosunetuzumab + CHOP | 40 | 40 |
| Total, other adverse events | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 38 | 38 |
| Total, other adverse events | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 22 | 22 |
| Total, serious adverse events | Group A1: Phase Ib Mosunetuzumab + CHOP | 3 | 3 |
| Total, serious adverse events | Group A2: Phase Ib Mosunetuzumab + CHOP | 4 | 4 |
| Total, serious adverse events | Group B: Phase Ib Mosunetuzumab + CHP-Pola | 6 | 8 |
| Total, serious adverse events | Group C: Phase II Mosunetuzumab + CHOP | 20 | 40 |
| Total, serious adverse events | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 24 | 38 |
| Total, serious adverse events | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 3 | 22 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03677141/event-totals